These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38872850)

  • 1. Serological Responses to
    Taggart M; Langworthy K; Hui S; Boyder C; Fulurija A; Morici M; Raby E; Manning L
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae272. PubMed ID: 38872850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-familial transmission of Streptococcus dysgalactiae subsp. equisimilis (SDSE): A first case report and review of the literature.
    Sunagawa K; Shirafuji T; Sun G; Arai R; Azuma H; Miyoshi-Akiyama T; Katano H
    J Infect Chemother; 2022 Jun; 28(6):819-822. PubMed ID: 35115237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of virulence factors and association with emm polymorphism or isolation site among beta-hemolytic group G Streptococcus dysgalactiae subspecies equisimilis.
    Lo HH; Cheng WS
    APMIS; 2015 Jan; 123(1):45-52. PubMed ID: 25244428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study.
    Bruun T; Oppegaard O; Kittang BR; Mylvaganam H; Langeland N; Skrede S
    Open Forum Infect Dis; 2016 Jan; 3(1):ofv181. PubMed ID: 26734653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive infection caused by Streptococcus dysgalactiae subsp. equisimilis: characteristics of strains and clinical features.
    Takahashi T; Ubukata K; Watanabe H
    J Infect Chemother; 2011 Feb; 17(1):1-10. PubMed ID: 20607346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of virulence genes to clinical manifestations and outcome in patients with Streptococcus dysgalactiae subspecies equisimilis bacteremia.
    Tsai CT; Chi CY; Ho CM; Lin PC; Chou CH; Wang JH; Wang JH; Lin HC; Tien N; Lin KH; Ho MW; Lu JJ
    J Microbiol Immunol Infect; 2014 Dec; 47(6):462-8. PubMed ID: 24210866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Characterisation of a Four-Plex Assay to Measure
    Keeley AJ; Carducci M; Massai L; Pizza M; de Silva TI; G Moriel D; Rossi O
    Methods Protoc; 2022 Jun; 5(4):. PubMed ID: 35893581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Streptococcus pyogenes virulence genes in Streptococcus dysgalactiae subsp. equisimilis from Vellore, India.
    Babbar A; Itzek A; Pieper DH; Nitsche-Schmitz DP
    Folia Microbiol (Praha); 2018 Sep; 63(5):581-586. PubMed ID: 29532420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, seasonal pattern, and clinical manifestations of Streptococcus dysgalactiae subspecies equisimilis bacteremia; a population-based study.
    Nevanlinna V; Huttunen R; Aittoniemi J; Luukkaala T; Rantala S
    Eur J Clin Microbiol Infect Dis; 2023 Jul; 42(7):819-825. PubMed ID: 37119347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptolysin O Deficiency in Streptococcus pyogenes M1T1
    Langshaw EL; Reynolds S; Ozberk V; Dooley J; Calcutt A; Zaman M; Walker MJ; Batzloff MR; Davies MR; Good MF; Pandey M
    mBio; 2023 Feb; 14(1):e0348822. PubMed ID: 36744883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptococcal toxic-shock syndrome due to Streptococcus dysgalactiae subspecies equisimilis in breast cancer-related lymphedema: a case report.
    Sumazaki M; Saito F; Ogata H; Yoshida M; Kubota Y; Magoshi S; Kaneko H
    J Med Case Rep; 2017 Jul; 11(1):191. PubMed ID: 28705211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational Design of a Glycoconjugate Vaccine against Group A
    Di Benedetto R; Mancini F; Carducci M; Gasperini G; Moriel DG; Saul A; Necchi F; Rappuoli R; Micoli F
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Group A Streptococcal Vaccine Candidate VAX-A1 Protects against Group B
    McCabe S; Bjånes E; Hendriks A; Wang Z; van Sorge NM; Pill-Pepe L; Bautista L; Chu E; Codée JDC; Fairman J; Kapoor N; Uchiyama S; Nizet V
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of emm types and antimicrobial susceptibility of Streptococcus dysgalactiae subsp. equisimilis in Austria.
    Leitner E; Zollner-Schwetz I; Zarfel G; Masoud-Landgraf L; Gehrer M; Wagner-Eibel U; Grisold AJ; Feierl G
    Int J Med Microbiol; 2015 Dec; 305(8):918-24. PubMed ID: 26507866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An eight-plex immunoassay for Group A streptococcus serology and vaccine development.
    Whitcombe AL; Han F; McAlister SM; Kirkham LS; Young PG; Ritchie SR; Atatoa Carr P; Proft T; Moreland NJ
    J Immunol Methods; 2022 Jan; 500():113194. PubMed ID: 34801540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Hyaluronate Lyase Involved in Pathogenicity of
    Nguyen VA; Ogura K; Matsue M; Takemoto N; Mukai K; Nakajima Y; Hoang TL; Iwata Y; Sakai N; Wada T; Hashimoto W; Okamoto S; Ichimura H
    Front Microbiol; 2020; 11():552418. PubMed ID: 33072013
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative genome analysis of three Group A
    Ishihara H; Ogura K; Nguyen VA; Miyoshi-Akiyama T; Okamoto S; Takemoto N
    J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33533709
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence, clinical characteristics, and outcomes of Streptococcus dysgalactiae subspecies equisimilis bacteremia in a tertiary hospital: comparison with S. agalactiae bacteremia.
    Park JH; Jung J; Kim MJ; Sung H; Kim MN; Chong YP; Kim SH; Lee SO; Kim YS; Woo JH; Choi SH
    Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2253-2258. PubMed ID: 31392445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative genomic analysis of Streptococcus dysgalactiae subspecies dysgalactiae, an occasional cause of zoonotic infection.
    Koh TH; Binte Abdul Rahman N; Sessions OM
    Pathology; 2020 Feb; 52(2):262-266. PubMed ID: 31859005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
    Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
    mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.